EFCCA is involved in this exciting project that will identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily living and Health-related quality of life (HRQoL) in ImmuneMediated Inflammatory Diseases such as IBD as well as other such as Rheumatoid Arthritis and Lupus and which will ultimately have a positive impact on the quality of life of these patients.
Background
The IDEA-FAST project is a 5½-year IMI2 project under Call H2020-JTI-IMI2-2018-15-two-stage – digital endpoints in neurodegenerative and immune-mediated diseases (total budget €42 Million) that starts in November 2019, run by a consortium of 46 partners across 15 countries in Europe. It received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853981. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
Work in progress
We have been participating in the bi-weekly meeting involving all members of the Consortium. Following the Kick-Off meeting in Newcastle in February 2020, the IDEA-FAST team worked hard to make the vision of the feasibility study come to life. By August 2020 the IDEA-FAST data management platform was launched and ready to receive data collected from the Feasibility Study. In the most recent development IDEA FAST agreed to collaborate withthe Mobilise - D project (IMI Project) to bring synergy and increase the impact and benefi ts of the digital health technologies developed by both projects. The collaboration will exploit common themes and approaches across the projects, to develop digital biomarkers in mobility, sleep and fatigue, including large observational studies involving diverse patient cohorts.
EFCCA also participated in the 4th IDEA-FAST General Assembly held in person in Barcelona on 16th-17th March 2023 with the whole consortium to push forward with the project objectives.
Go to project website or follow on Twitter and LinkedIn for more info.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853995. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The content provided on this page reflects only the author's view and neither the IMI JU nor the European Commission are responsible for any use that may be made of the information it contains.
